Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

22.7%

5 terminated/withdrawn out of 22 trials

Success Rate

77.3%

-9.2% vs industry average

Late-Stage Pipeline

45%

10 trials in Phase 3/4

Results Transparency

88%

15 of 17 completed trials have results

Key Signals

15 with results

Enrollment Performance

Analytics

Phase 3

10(45.5%)

Phase 2

8(36.4%)

Phase 1

4(18.2%)

22Total

Phase 3(10)

Phase 2(8)

Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT02768662Phase 3Terminated

A 6-Month Extension Study of OTO-104 in Meniere's Disease

Role: lead

NCT02717442Phase 3Terminated

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Role: lead

NCT02612337Phase 3Completed

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Role: lead

NCT04829214Phase 2Completed

OTO-313 in Subjects With Unilateral Subjective Tinnitus

Role: lead

NCT03918109Phase 1Completed

OTO-313 in Subjects With Subjective Tinnitus

Role: lead

NCT02706730Phase 3Terminated

A 6-Month Extension Study of OTO-104 in Meniere's Disease

Role: lead

NCT03664674Phase 3Completed

Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Role: lead

NCT04129775Phase 1Completed

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

Role: lead

NCT02408796Phase 2Completed

Open-Label Study of OTO-201 for Treatment of AOMT

Role: lead

NCT02600559Phase 3Completed

Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes

Role: lead

NCT02719158Phase 2Completed

Dose Ranging Study of OTO-201 in AOMT

Role: lead

NCT02801370Phase 3Completed

Phase 3 Study of OTO-201 in Acute Otitis Externa

Role: lead

NCT02350998Phase 3Completed

Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration

Role: lead

NCT02511561Phase 2Completed

OTO-201 for the Treatment of Otitis Externa

Role: lead

NCT02997189Phase 2Terminated

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

Role: lead

NCT02740387Phase 2Terminated

Open Label Study of OTO-104 in Subjects With Meniere's Disease

Role: lead

NCT02265393Phase 2Completed

A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom

Role: lead

NCT01949155Phase 3Completed

OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Role: lead

NCT01949142Phase 3Completed

OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Role: lead

NCT01412177Phase 2Completed

OTO-104 for the Treatment of Meniere's Disease

Role: lead